SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (28647)3/31/1999 11:48:00 PM
From: Cheryl Galt  Read Replies (1) | Respond to of 32384
 
Thanks, J.D. ... I forgot about that, and it accounts for $12.5M
of the approx. 30M growth in cash.

The cash burn has been running over $20M/Q lately.

But with the year-end cash balance of $72.5M,
$70M remaining on the Elan line of credit,
some sales revenue coming in, and R&D and milestones from partners
-- it looks likes Ligand has at least two years of financial security,
even if Targretin is slow to pan out.

Cheryl


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News